Lifeway Foods, Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-QSB) for the period ended September 30, 1998. Lifeway Foods, Inc. is a small business issuer incorporated in Illinois, producing and distributing dairy products including Kefir, drinkable yogurt, farmer's cheese, and "Sweet Kiss." The company operates a production facility and a "Russian" theme restaurant/supper club. Products are distributed in the Chicago area, the U.S., Canada, and Eastern Europe.
Key Financial Metrics (Nine Months Ended Sept 30, 1998)
- Revenue (Sales): $5,072,862
- Net Income: $628,770
- Earnings Per Share (EPS): $0.17
- Gross Profit: $2,759,382 (Gross Margin: ~54.4%)
- Operating Income: $1,079,388
- Cash and Cash Equivalents: $695,799
- Working Capital: $1,682,952
- Total Debt: $1,395,051 (Current maturities: $266,964; Long-term: $1,128,087)
- Net Cash from Operating Activities: $534,880
- Net Cash Used in Investing Activities: ($341,921)
Material Changes vs. Prior Period
- Sales Growth: Sales increased by $680,661 (15.5%) compared to the nine months ended September 30, 1997, driven by increased volume and price increases.
- Cost of Goods Sold (COGS): COGS decreased by $93,490 despite higher sales, attributed to a favorable product mix shift enabled by a new production facility.
- Operating Expenses: Increased by $558,922 (49.9%) primarily due to expenses associated with the new production facility.
- Other Income: Decreased significantly from $214,058 in the prior year to $0. The prior year figure included rent revenue from a tenant occupying property the company now uses for its own operations.
- Net Income: Remained relatively flat, increasing only $758 year-over-year, as sales gains were offset by higher operating expenses and the loss of rental income.
Outlook, Risks, and Unusual Items
- Debt Refinancing: Several mortgage notes are due in 1998. Management intends to refinance these obligations during the year.
- New Product Rights: In October 1998, the company finalized a sublicense agreement with GalaGen, Inc., obtaining exclusive worldwide rights to produce kefir-based products containing immunoglobulins (e.g., "Basic Plus"). This involves a $10,000 payment and a 1% royalty on net sales.
- Capital Expenditures: Cash used in investing activities decreased significantly ($700,483) compared to the prior year, reflecting a slowdown in equipment purchases for the new facility.
- Management Commentary: Management reports no known trends that would negatively impact future sales or earnings and notes no material seasonal fluctuations.
Investor Verification Checklist
- Verify the company's ability to refinance the $266,964 in current debt maturities and the balloon payment of $184,900 due in November 1998.
- Monitor the commercial performance and royalty obligations associated with the new "Basic Plus" product line.
- Assess the sustainability of the increased operating expenses related to the new production facility against future revenue growth.
- Review the concentration of credit risk, noting that two customers accounted for significant portions of sales and receivables in the prior year.